This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HCA Healthcare's (HCA) Galen College Adds 8th New Facility
by Zacks Equity Research
HCA Healthcare's (HCA) Galen College nursing campus addition comes when the country is suffering from a nursing shortage.
Humana (HUM) to Offer Home Care Model to Virginia's MA Members
by Zacks Equity Research
Humana (HUM) expands the customer reach of its unit's value-based home care model to Virginia, with an aim to offer better in-home care services to the state's Medicare Advantage members.
Here's Why Investors Should Bet on Cigna (CI) Stock Now
by Zacks Equity Research
Cigna (CI) expects 2022 medical customers to grow by a minimum of 725,000, suggesting an upside from the prior projection.
UnitedHealth (UNH) Rewards Shareholders With 13.8% Dividend Hike
by Zacks Equity Research
UnitedHealth's (UNH) strong balance sheet supports its endeavors to return shareholders' funds.
Encompass Health (EHC) Updates 2022 Guidance: Dips 5.4%
by Zacks Equity Research
Encompass Health (EHC) expects to retain its cash dividend routine. However, the amount might decline to reflect the spin-off of the home health and hospice business.
Ensign Group (ENSG) Up 3.7% in 30 Days: More Room to Rally?
by Zacks Equity Research
Ensign Group's (ENSG) rising profits from Skilled Services business are a major positive.
HCA Healthcare's (HCA) Utah Acquisition Faces Fed Roadblocks
by Zacks Equity Research
The trade watchdog expects HCA Healthcare's (HCA) Utah acquisition to induce market concentration and eliminate Steward Health Care as a low-cost competitor.
Zacks Industry Outlook Highlights UnitedHealth Group Anthem, Humana, Centene, and Select Medical
by Zacks Equity Research
UnitedHealth Group, Anthem, Humana, Centene, and Select Medical are part of Zacks Industry Outlook article.
5 HMO Stocks Set to Gain From Membership Growth, M&A Strategy
by Debasmita Chatterjee
Rising membership and a rapidly growing aging U.S. population are likely to drive the performances of the Zacks Medical-HMO industry players. UNH, ANTM, HUM, CNC and SEM are poised to benefit from improved operational efficiencies.
Wall Street Analysts Believe Select Medical (SEM) Could Rally 75%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 74.5% upside potential for Select Medical (SEM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The Joint (JYNT) Acquires 4 Franchised Facilities, Down 5%
by Zacks Equity Research
The Joint (JYNT) anticipates the new acquisition value in Scottsdale to match the price of its previous purchases.
Humana (HUM) Expands JV, To Invest $1.2B, Eyes 100 New Clinics
by Zacks Equity Research
Through the first JV, Humana (HUM) and its partner are pumping $800 million into developing 67 facilities by early 2023.
Wall Street Analysts Think Select Medical (SEM) Could Surge 91%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Select Medical (SEM) points to a 91.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Select Medical (SEM) Shares Up on Q1 Earnings & Revenue Beat
by Zacks Equity Research
Select Medical's (SEM) first-quarter earnings benefit from higher patient visits and sound segmental contributions to revenues, partly offset by elevated labor expenses.
Select Medical (SEM) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of 27.59% and 2.96%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Molina (MOH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 3.38% and 3.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Select Medical (SEM) to Open 31-Bed Hospital in Northern Ohio
by Zacks Equity Research
The new facility is likely to be a satellite unit of Select Medical Holdings' (SEM) Regency Hospital Toledou, located in Sylvania, OH.
Select Medical (SEM) Q4 Earnings Beat on Higher Admissions
by Zacks Equity Research
Select Medical's (SEM) fourth-quarter results reflect solid revenues driven by robust contributions from all its segments, partly offset by higher costs and expenses.
Select Medical (SEM) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of 27.59% and 0.07%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Select Medical (SEM) Q4 Earnings Expected to Decline
by Zacks Equity Research
Select Medical (SEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Centene (CNC) Q4 Earnings Beat Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of 3.06% and 0.12%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Select Medical (SEM) '21 Sales View Up, Labor Costs Ail Profits
by Zacks Equity Research
Select Medical Holdings (SEM) estimates net operating revenues for 2021 to be $6.2 billion, up from the previous expectations.
Humana (HUM) to Buy Back Shares of $1B to Add Shareholder Value
by Zacks Equity Research
Humana (HUM) to buy back shares worth $1 billion as part of its $3-billion share repurchase plan announced in February 2021. This suggests its commitment toward delivering a long-term shareholder value.
Why Seasoned Investors are Retaining Community Health (CYH)
by Zacks Equity Research
Community Health Systems (CYH) is focused on making strategic acquisitions to boost its business through inorganic growth.
Select Medical's (SEM) Rising Stake in Concentra to Aid
by Zacks Equity Research
Select Medical Holdings (SEM) acquires the remaining Concentra stake from equity holders for $625.6 million.